Results of combination treatment with pegylated interferon and ribavirin in cirrhotic patients with hepatitis C infection

Abstract: Background: The treatment of hepatitis C patients with advanced cirrhotic liver disease remains challenging and data on the outcome of treatment for this patient group is limited.

[1]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[2]  William M. Lee,et al.  Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. , 2004, Gastroenterology.

[3]  E. Christensen,et al.  Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients , 2002, American Journal of Gastroenterology.

[4]  M. Tong,et al.  The long‐term outcomes of patients with compensated hepatitis C virus–related cirrhosis and history of parenteral exposure in the united states , 1999, Hepatology.

[5]  Inda,et al.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. , 1999, The New England journal of medicine.

[6]  J. Emparanza,et al.  [The prevalence of hepatitis C virus infection]. , 1998, Gastroenterologia y hepatologia.

[7]  G. Everson.  Management of cirrhosis due to chronic hepatitis C. , 2005, Journal of hepatology.

[8]  N. LaRusso,et al.  Rab3D, a small GTP–binding protein implicated in regulated secretion, is associated with the transcytotic pathway in rat hepatocytes , 2000, Hepatology.

[9]  G. Everson.  Treatment of hepatitis C in patients who have decompensated cirrhosis. , 2005, Clinics in liver disease.

[10]  O. Chazouilleres,et al.  Determinants of outcome of compensated hepatitis C virus‐related cirrhosis , 1998, Hepatology.

[11]  J. Hoofnagle,et al.  Hepatitis C in African Americans: summary of a workshop. , 2000, Gastroenterology.

[12]  L. Ferrell,et al.  HCV-related fibrosis progression following liver transplantation: increase in recent years. , 2000, Journal of hepatology.

[13]  J. Kalbfleisch,et al.  A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C , 2003, Hepatology.

[14]  A. Bhalla,et al.  Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. , 1997, Gastroenterology.

[15]  J. George,et al.  Effectiveness of interferon alfa‐2b/ribavirin combination therapy for chronic hepatitis C in a clinic setting , 2003, The Medical journal of Australia.

[16]  G. Everson,et al.  Maintenance interferon for chronic hepatitis C: More issues than answers? , 2000, Hepatology.

[17]  J. Cadranel,et al.  Traitement de l'hépatite chronique C par interféron alpha et ribavirine , 2008 .

[18]  A. Pariente,et al.  [Treatment of chronic hepatitis C with interferon alpha and ribavirin. Results in "real life"]. , 2003, Gastroenterologie clinique et biologique.

[19]  T. Wright.  Treatment of patients with hepatitis C and cirrhosis , 2002, Hepatology.

[20]  N. Terrault,et al.  A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus–infected patients awaiting liver transplantation , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[21]  P. Marcellin,et al.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.

[22]  P. Marcellin,et al.  Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin , 2005, European journal of gastroenterology & hepatology.

[23]  P. Marcellin,et al.  Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus , 1998, The Lancet.

[24]  S. Zeuzem.  Heterogeneous Virologic Response Rates to Interferon-Based Therapy in Patients with Chronic Hepatitis C: Who Responds Less Well? , 2004, Annals of Internal Medicine.

[25]  G. Fattovich,et al.  Therapy of hepatitis C: Patients with cirrhosis , 1997, Hepatology.

[26]  M. Shiffman.  Retreatment of patients with chronic hepatitis C , 2002, Hepatology.

[27]  M. Shiffman,et al.  Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. , 2000, The New England journal of medicine.

[28]  E L Murphy,et al.  Prevalence of hepatitis C virus infection in the United States. , 1999, The New England journal of medicine.

[29]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[30]  Stefan Zeuzem.  Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? , 2004 .

[31]  B. Portmann,et al.  Acute liver failure associated with antiretroviral treatment for HIV: a report of six cases. , 2002, Journal of hepatology.

[32]  J. Albrecht,et al.  The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. , 2000, Gastroenterology.

[33]  J. Berlin,et al.  The association between hepatitis C infection and survival after orthotopic liver transplantation. , 2002, Gastroenterology.